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Context: Congenital pituitary hormone deficiencies with syndromic phenotypes and/or familial 
occurrence suggest genetic hypopituitarism; however, in many such patients the underlying 
molecular basis of the disease remains unknown.
Objective: To describe patients with syndromic hypopituitarism due to biallelic loss-of-function 
variants in TBC1D32, a gene implicated in Sonic Hedgehog (Shh) signaling.
Setting: Referral center.
Patients: A Finnish family of 2 siblings with panhypopituitarism, absent anterior pituitary, and 
mild craniofacial dysmorphism, and a Pakistani family with a proband with growth hormone 
deficiency, anterior pituitary hypoplasia, and developmental delay.
Interventions: The patients were investigated by whole genome sequencing. Expression 
profiling of TBC1D32 in human fetal brain was performed through in situ hybridization. Stable 
and dynamic protein-protein interaction partners of TBC1D32 were investigated in HEK cells 
followed by mass spectrometry analyses.
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Main Outcome Measures: Genetic and phenotypic features of patients with biallelic loss-of-
function mutations in TBC1D32.
Results: The Finnish patients harboured compound heterozygous loss-of-function variants 
(c.1165_1166dup p.(Gln390Phefs*32) and c.2151del p.(Lys717Asnfs*29)) in TBC1D32; the 
Pakistani proband carried a known pathogenic homozygous TBC1D32 splice-site variant 
c.1372 + 1G > A p.(Arg411_Gly458del), as did a fetus with a cleft lip and partial intestinal 
malrotation from a terminated pregnancy within the same pedigree. TBC1D32 was expressed in 
the developing hypothalamus, Rathke’s pouch, and areas of the hindbrain. TBC1D32 interacted 
with proteins implicated in cilium assembly, Shh signaling, and brain development.
Conclusions: Biallelic TBC1D32 variants underlie syndromic hypopituitarism, and the underlying 
mechanism may be via disrupted Shh signaling. (J Clin Endocrinol Metab 105: 1748–1758, 2020)
Key Words:  TBC1D32, hypopituitarism, Sonic Hedgehog signaling, ciliopathy, retinal dystrophy
P ituitary hormone deficiencies in combination with extrapituitary manifestations suggest a role 
for genes involved in the early patterning of the pi-
tuitary, such as HESX1, PITX2, OTX2, SOX2, 
SOX3, LHX3, LHX4, GLI2, and FGF8 that form a 
complex cascade culminating in the formation of mid-
line anterior brain and craniofacial structures (1–6). 
However, in the majority of cases, the underlying mo-
lecular basis remains unknown. The Sonic Hedgehog 
(Shh) signaling pathway is essential for central nervous 
system (CNS), early pituitary and ventral forebrain de-
velopment in mice. Pathogenic variants in components 
of the SHH pathway have been described in patients 
with holoprosencephaly, isolated congenital hypo-
pituitarism, and cranial/midline facial abnormalities 
(7). Variably penetrant variants in GLI2, a zinc-finger 
transcription factor that mediates SHH transduc-
tion, have been described in patients with variable 
holoprosencephaly phenotypes, including micro-
cephaly, bilateral cleft lip/palate, postaxial polydac-
tyly, optic nerve hypoplasia, and an absent/hypoplastic 
pituitary with isolated or multiple anterior pituitary 
hormone deficiencies (8). GLI2 variants are not infre-
quently associated with combined pituitary hormone 
deficiency in isolation, without midline defects or other 
features of holoprosencephaly (9).
Extrapituitary phenotypic features in patients with 
complex forms of hypopituitarism may be suggestive 
of certain genotypes, and are important in guiding mo-
lecular studies (1). Herein, we utilized whole genome 
sequencing (WGS) to identify the molecular basis of 
hypopituitarism in 3 patients who presented with pitu-
itary hormone deficiencies and craniofacial phenotypes, 
together with variable limb, intellectual, and retinal 
phenotypes. Our results show that the patients car-
ried biallelic loss-of-function variants in TBC1D32, a 
gene implicated in ciliary function and Sonic Hedgehog 
signaling (10, 11). We subsequently investigated the 
expression of TBC1D32 in the developing human brain 
and examined its protein–protein interaction partners 
to gain insight into the putative disease mechanism 
by which variants in this gene cause such a complex 
phenotype.
Materials and Methods
Patients and clinical data
We investigated a Finnish family (Pedigree I, Fig.  1A) 
including 2 affected siblings with an absent anterior pituitary, 
ectopic posterior pituitary, mild craniofacial dysmorphism, and 
progressive retinal dystrophy, and a consanguineous Pakistani 
family (Pedigree II, Fig. 1A) with a proband who presented with 
developmental delay and features suggestive of oral-facial-digital 
syndrome (OFDS) associated with growth hormone (GH) defi-
ciency. Detailed pedigrees are documented in the Results section.
Genetics
Genomic DNA was extracted from the subject’s peripheral 
blood leukocytes. WGS of the Finnish family was performed 
in the Beijing Genomic Institute (BGI, Shenzhen, China) with 
Illumina HiSeq X Ten technology. On the basis of pedigree I, 
a recessive mode of inheritance was assumed to be most likely. 
Therefore, filtering analysis of the WGS data searched for 
either homozygous or compound heterozygous variants that 
were present in both patients, where the parents carried only 1 
in a heterozygous state. We only considered non-synonymous 
or splice site variants that were novel or had frequencies of less 
than 0.5%. WGS of the Pakistani family was carried out via 
the 100 000 Genomes Project: Protocol v3, Genomics England. 
(12) A number of standardized panels from Genomics England 
PanelApp were subsequently applied to the data from Pedigree 
II (13), including a panel for rare, multisystem ciliopathy dis-
orders (v1.28). Targeted sequence analysis by bidirectional 
Sanger sequencing was used to confirm the presence and the 
mono-/biallelicity of the likely pathogenic variants.
Reverse transcriptase polymerase chain reaction 
analysis
A 310-bp fragment of the TBC1D32 transcript was ampli-
fied from the human pituitary gland and hypothalamic cDNA, 
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Figure 1. A: The pedigrees of our patients with hypopituitarism and biallelic TBC1D32 variants. I: the Finnish pedigree; II: the Pakistani pedigree. 
Patients I.3 and I.5 carried compound heterozygous and patients II.8 and II.9 carried homozygous variants in TBC1D32. The parents were 
heterozygous carriers of the respective variants. B: (i) and (ii) the MRIs of the 2 Finnish patients. Upper row, Patient I.3: Sagittal (a) and coronal 
(b) T1 images without contrast enhancement. The sella turcica and the pituitary gland are not identifiable. Neurohypophyseal bright tissue is seen 
near the tuber cinereum (arrow). Lower row, Patient I.5: Sagittal (a) and axial (b) T1 images without contrast enhancement. The sella turcica and 
the pituitary gland are absent. Potentially neurohypophyseal bright tissue is seen near the tuber cinereum (arrow). (iii) MRI of patient II.8. Upper 
row, Patient II.8: Sagittal (a) T1 image showing partial agenesis of corpus callosum (CC), small interhemispheric lipoma (L), small anterior pituitary 
(AP), and small ectopic posterior pituitary (PP). Lower row: coronal image showing dysplasia of the cerebellar vermis (arrow) with an abnormal 
left cerebellum. The “molar tooth” sign of Joubert syndrome is also shown (filled arrow). C: Clinical photos of the patients. (i) Patient I.3 at 
2.4 years of age. Note the prominent forehead and the low-set, posteriorly rotated ears; (ii) Patient I.5 presented with prominent forehead, large 
anterior fontanelle, and low-set ears in infancy; (iii) Patient I.5 at 10.5 years of age; (iv) Patient II.8 in infancy showing a prominent forehead with 
hypertelorism, low-set ears, flat nasal bridge and anteverted nares; (v) Patient II.8 at 5.5 years of age.
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respectively, (QUICK-Clone pituitary cDNA, Takarabio, 
1.5µl / reaction; Hypothalamus Marathon®-Ready cDNA, 
Takarabio, 1.5ul / reaction) using cDNA-specific primers. 
GAPDH served as a reference gene. The polymerase chain re-
action (PCR) products were visualized on a 1% agarose gel.
Human embryonic expression analysis: in situ 
hybridisation
A purified pT7T3D-PacI vector containing a portion of 
the human wild-type TBC1D32 cDNA (IMAGE ID: 505 804) 
(Source Bioscience) was used to make both the antisense and 
control sense digoxigenin-labeled TBC1D32 RNA probes. 
Human embryonic tissue sections were selected at Carnegie 
stage (CS) 19, 20, and 23 (equivalent to gestational age 6, 7, 
and 8 weeks into development). respectively, obtained from 
the Human Developmental Biology Resource (HDBR). Due 
to limited access to human embryonic tissue, we were re-
stricted to these 3 stages during embryogenesis. The in situ 
hybridisation protocol was performed as previously described 
(14) to generate a human embryonic expression brain profile 
incorporating the hypothalamo-pituitary region. More de-
tailed information on restriction enzymes and RNA sequences 
are available upon request.
Cell culture, affinity purification, and mass 
spectrometry
The TBC1D32 PCR product with flanking at B sites 
was used for BP reaction to generate the gateway compat-
ible entry clone. LR recombination was performed between 
the entry clones and the destination vector to generate the 
MAC-tag tagged TBC1D32 expression vector (15). Culture 
of Flp-In T-REx 293 (ThermoFischer Scientific,  Waltham, 
Massachusettes) cell lines, transfection, and stable cell line 
selection were performed as previously described (16, 17). 
Affinity purification (AP) and BioID experiments, together 
with mass spectrometry (MS) analysis, were performed as pre-
viously described (18).
Ethics
The study was approved by the Ethics Committee of the 
Hospital District of Helsinki and Uusimaa (Committee for 
women, children and psychiatry, approval HUS/3325/2017). 
Full informed consent was obtained from the United Kingdom 
family to participate in the 100 000 Genomes Project. The 
guardians of the patients gave their written informed consent 
to participate in the phenotyping and genetic studies. Written 
consent for publication of photographs was also obtained 
from the parents of the proband in the Pakistani family and 
from the parents of the Finnish family.
Results
Pedigree I
A Finnish family with healthy parents, 2 affected chil-
dren and 1 unaffected child, is shown in Fig. 1A. Patient 
I.3 (Fig.  1A) was born at 42 + 1 weeks gestation fol-
lowing an uncomplicated pregnancy. Labor was induced 
due to postmaturity and proceeded to an emergency cae-
sarean section due to changes in the cardiotocography 
(CTG)-scan. The patient had birth asphyxia with Apgar 
scores of 1/4/5 at 0/5/15 minutes of age, respectively. 
He was hydropic, hypotonic, and had recurrent hypo-
glycemia, jaundice, and transient diabetes insipidus. 
Although the post-term ultrasound scan at gestational 
week (GW) 41 + 1 had shown short fetal femoral bones, 
his birth length (50.2 cm, -1.0 SDS), weight (3.51 kg, 
-0.8 SDS), and head circumference (38.0 cm, +1.6 SDS) 
were within normal limits. He was treated with inter-
mittent continuous positive airway pressure (nasal-
CPAP), short intubation and phototherapy, and had a 
patent ductus arteriosus (PDA), which closed spontan-
eously, with no other structural cardiac anomalies. He 
had micropenis and bilateral cryptorchidism (corrected 
surgically before 2 years of age). During the first weeks 
of life, he was diagnosed with growth hormone (GH), 
adrenocorticotropin (ACTH), thyroid-stimulating 
hormone (TSH), and gonadotropin deficiencies 
(Table  1). Treatment with L-thyroxin, hydrocortisone, 
and GH was commenced immediately. Brain magnetic 
resonance imaging (MRI) revealed that the sella turcica 
and the hypophysis were not identifiable, and an ectopic 
or undescended neurohypophysis was present near the 
tuber cinereum (Fig. 1B). The optic chiasm was some-
what narrow, although the optic nerves were normal. 
In addition to the endocrine abnormalities, he had com-
municating hydrocephalus, developmental delay, and 
slight bilateral astigmatism. He was partially dependent 
on nasogastric tube feeding up to 5 months of age and 
had severe secretory otitis media with insertion of grom-
mets at the age of 1  year. At 3  years of age, he died 
unexpectedly following infection, in spite of adequate 
hydrocortisone substitution.
Patient I.5 (Fig.  1A), the sister of I.3, was born by 
vaginal delivery at 41 + 6 weeks gestation following 
an uncomplicated pregnancy. Her birth length, weight, 
and head circumference were 51 cm (-0.1 SDS), 3.90 kg 
(+0.1 SDS), and 37 cm (+1.3 SDS), respectively. She had 
a prominent forehead, large anterior fontanelle, and 
deep set eyes, with low-set ears (Fig. 1C). She had hypo-
tonia, hypoglycemia, and metabolic acidosis. Endocrine 
investigations were initiated soon after birth due to her 
phenotype and a positive family history of hypopituit-
arism. She was diagnosed with GH and TSH deficiencies 
(Table 1) and has received GH and L-thyroxin substi-
tution treatment since the neonatal period. In addition, 
the patient was commenced on oral hydrocortisone due 
to the family history and the possibility of progressive 
ACTH deficiency. Magnetic resonance imaging revealed 
an absent sella turcica and anterior pituitary gland, and 
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potential neurohypophyseal tissue was detected close 
to the tuber cinereum (Fig.  1B). She had insertion of 
grommets before 1 year of age. Cardiac ultrasound and 
24-hour electrocardiogram (ECG) were both normal 
at the age of 6 months. Interestingly, she has also been 
diagnosed with progressive retinal dystrophy, motor 
delay, neuromuscular scoliosis, and discrepancy of her 
lower limb length. Her upper jaw is narrow with mis-
aligned teeth, of which 3 have by now been extracted. 
Due to marked feeding difficulties, she underwent speech 
therapy until 6 years of age. At the age of 8 years, she 
was prepubertal and exhibited dysmorphic craniofacial 
features, including a prominent forehead, wide nasal 
bridge, short upturned nose, hypertelorism, downward 
slanting palpebral fissures, posteriorly-rotated ears, low 
hairline, and nuchal hair (Fig.  1C). She had a barrel-
like chest and widely spaced nipples. Hypermobility 
was noted in the upper limbs. Her finger pads were 
prominent and she had fingernail clubbing. There was 
slight syndactyly of the 2nd and 3rd toes, and a bilateral 
sandal gap. Her cognitive development is normal.
Whole genome sequencing data had an average 
sequencing depth of at least 28.83 and 99.01% 
coverage for each sample. Both I.3 and I.5 car-
ried compound heterozygous variants predicted 
to lead to frameshifts and premature stop codons, 
c.1165_1166dup p.(Gln390Phefs*32) and c.2151del 
p.(Lys717Asnfs*29), in the TBC1D32 (NM_152730.5) 
gene (Fig. 1A). The mother (I.1) carried the c.2151del 
variant, and the father (I.2) and healthy brother (I.4) 
carried the c.1165_1166dup variant in a heterozy-
gous state. The c.1165_1166dup p.(Gln390Phefs*32) 
(rs546631812) variant is reported in the gnomAD data-
base with a minor allele frequency of 0.001090. The 
c.2151del p.(Lys717Asnfs*29) variant is absent from 
the gnomAD, ExAC, and SISu Project databases.
Pedigree II
An independent consanguineous pedigree with a loss-
of-function variant in TBC1D32 is presented in Fig. 1A. 
The proband (II.8) is a 5-year-old girl, born to second 
cousin Pakistani parents (II.6 and II.7). Antenatal 
scans showed short long bones (femur length below 
3rd percentile), midline cystic changes in the brain, and 
polyhydramnios. Her birth weight at term was 3.27 kg 
(9th percentile; -0.4 SDS). She was noted to have dis-
tinctive facial features with a broad forehead, wide 
anterior fontanelle, hypertelorism, low-set ears, flat 
nasal bridge, anteverted nares, slight midline groove 
on the tongue, serrated gums (but not overt frenulae), 
ankyloglossia, and a high, narrow palate (Fig.  1C). 
Other findings included postaxial polydactyly on her 
left hand, small hands, and apparent rhizomelic short-
ening of the limbs. After failure to pass a nasogastric 
tube she was found to have left-sided choanal atresia. 
An MRI brain scan performed at birth was reported as 
Table 1. Biochemical testing of the pituitary hormone secretion in Patients I.3 and I.5
Patient I.3 Patient I.5
 Age (Days) Test Result [NR] Age (Days) Test Result [NR]
Growth hormone     
Serum IGF1 (nmol/L) 8 7 [na] 20 <3 [7–43]
Fasting serum GH during hypoglycemia (ug/L) 8 <0.03 6 0.20
Maximum arginine-stimulated serum GH (ug/L) - NA 26 0.23
ACTH     
Plasma ACTH (ng/L) 14 <5a [10–50] 11 15a [<46]
Serum cortisol (nmol/L) 1 <20 [150–650] 11 121a [30–632]
Maximum synacthen-stimulated plasma cortisol 
(ACTH neo test) (nmol/L)
1 <20 11 638a
TSH     
Serum free T4 (pmol/L) 4 5.3 [9–19] 20 9.9 [8–25]
Serum TSH (mU/L) 4 0.002 [0.6–10] 20 2.65 [0.6–10]
Serum TSH during TRH provocation test (at 
0/20/60 min) (mU/L)
 NA 26 2.58/4.63/4.73
Gonadotropins     
Serum inhibin B (ng/L) 2 175 - NA
Serum FSH (IU/L) 18 <0.10 - NA
Maximum serum FSH during GnRH provocation 
test (IU/L)
18 0.2 - NA
Serum LH (IU/L) 18 <0.10 - NA
Maximum serum LH during GnRH provocation 
test (IU/L)
18 <0.10 - NA
Abbreviations: NA, not available; NR, normal range. 
aMeasured during exogenous cortisone treatment.
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showing partial agenesis of the corpus callosum and a 
very small anterior pituitary gland and optic chiasm, 
consistent with septo-optic dysplasia (Fig.  1B). There 
was dysplasia of the cerebellar vermis with a midline 
cleft, similar to MRI scan findings observed in Joubert 
syndrome. Her brainstem was small, with a small 
interhemispheric lipoma. A skeletal survey, renal ultra-
sound and echocardiogram were all normal. Her head 
circumference at 6 months was 42.5 cm (+0.1 SDS). Her 
growth was suboptimal with a GH concentration of 0.6 
ug/L in response to hypoglycaemia with an undetect-
able serum IGF-1 and a low IGFBP3 (0.75 mg/L; NR 
0.8–3.9). Her cortisol was normal at 464 nmol/L. She 
was commenced on GH treatment at 13 months of age 
(height SDS -5.0) with a good response. At 4.75 years, 
her height was 91.2cm (-3.2 SDS).
She has global developmental delay and attends a 
special needs school. She sat independently at 2 years. 
However, at 5.5 years she is still unable to mobilize inde-
pendently, although she will stand with support. She does 
not vocalize but understands familiar words. At 3 years 
of age, she had grommet insertion for bilateral glue ear 
and her hearing is currently normal. She has a bilateral 
divergent squint and severe cerebral visual impairment 
with reduced visual acuity but with normal retinal re-
sponses on electroretinogram. Whole genome sequencing 
showed that patient II.8 was homozygous for a variant 
(NM_152730.5; c.1372 + 1G > A) in TBC1D32 
(Fig. 1A). This variant was previously reported in associ-
ation with OFDS type IX (19) and is predicted to cause 
aberrant splicing by abolishing the exon 12 splice site, 
resulting in exon skipping of exon 12, with a truncation 
of the protein, p.(Arg411_Gly458del), and was there-
fore considered pathogenic. In her mother’s second preg-
nancy, the fetus (II.9) was found to have midline facial 
clefting and a femoral length below the 3rd percentile 
on ultrasound scan at 20 weeks gestation. The parents 
opted for a termination of the pregnancy. Postmortem 
examination showed a female fetus with midline cleft 
lip and partial intestinal malrotation. Targeted sequence 
analysis by bidirectional Sanger sequencing confirmed 
the presence of the homozygous variant in both the pro-
band and fetus (Fig. 1A). Parental testing, also by Sanger 
sequencing, confirmed their carrier status. Subsequently, 
the mother has given birth to healthy twin boys, who 
have not been genetically tested.
Human embryonic and adult TBC1D32 expression 
analysis
In situ hybridization studies showed that human 
TBC1D32 expression during embryonic brain develop-
ment is not prominent in the hypothalamus or Rathke’s 
pouch at Carnegie stage (CS) 19 or 20 (Fig.  2A–B). 
However, at CS23, TBC1D32 is expressed in the hypo-
thalamus, Rathke’s pouch, trigeminal ganglia, and choroid 
plexus (Fig.  2C,D), with strong expression throughout 
the hindbrain and thalamus at this stage (Fig.  2D). 
Additionally, TBC1D32 is expressed in both adult human 
pituitary and hypothalamic cDNA libraries (Fig. 3).
Protein–protein interaction partners of TBC1D32
We employed a MAC-tag approach (15) to compre-
hensively identify the interaction partners of TBC1D32 
(a.k.a broad-minded, BROMI) by performing affinity 
purification (AP) and proximity labeling (BioID), fol-
lowed by MS. Using a comparative statistical ana-
lysis (15), we identified a total of 81 high confidence 
interacting proteins (HCIPs) (20), and subsequently, 
the DAVID functional annotation clustering tool (21) 
and primary cilium database (22) were used to group 
the related proteins. The results are shown in Fig. 4. In 
brief, the 81 interactors were mapped to 13 different 
cellular gene ontology classes: hedgehog signaling, 
cilium assembly, extracellular exosome, membrane, 
small GTPase-mediated signal transduction, trans-
port, cell cycle, brain development, oxidation reduction 
process, positive regulation of cytokinesis, transmem-
brane transporter activity, acquired immunodeficiency 
syndrome, and intracellular protein transport. The ana-
lysis disclosed 25 novel interactors of TBC1D32 that 
were grouped in the following six classes: transport; 
small GTPase mediated signal transduction; membrane; 
intracellular protein transport; transmembrane trans-
porter activity; extracellular exosome (Fig. 4). We per-
formed both AP and proximity labeling (BioID) coupled 
with MS for TBC1D32. The TBC proteins are a group 
of Rab-GAP (GTPase-activating protein) proteins, 
which are involved in the plasma membrane-endosome 
trafficking processes (23). Another critical group of 
proteins interacting with TBC1D32 (13 prey proteins) 
belongs to acquired immune deficiency syndrome and 
provides a putative link between the immune system 
and TBC1D32 function. Notably, 4 interacting proteins 
were associated with the oxidation-reduction process, 
and 3 proteins were linked to brain development.
Discussion
To date, biallelic TBC1D32 variants have been described 
in 1 male patient with severe facial and ocular pheno-
types, microcephaly, postaxial polydactyly, and CNS ab-
normalities, including the absence of the pituitary gland 
with subsequent panhypopituitarism (19). Herein, we 
describe phenotypic features of 3 children and 1 aborted 
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fetus from 2 unrelated pedigrees that are affected by 
biallelic loss-of-function variants in TBC1D32. Our 
results, together with those of Adly et al, confirm that 
TBC1D32 variants underlie a recessive disorder demar-
cated by severe but highly variable expression of mid-
line defects, including congenital hypopituitarism due to 
abnormal hypothalamo-pituitary development.
Oral-facial-digital syndromes are clinically and genetic-
ally heterogeneous ciliopathies characterized by abnormal-
ities of the face, oral cavity, and extremities (24). To date, at 
least 13 OFDS subtypes and 16 associated genes have been 
reported (24, 25). Comparison of the phenotypic features 
of the patients in our study and the patient with OFDS 
type IX reported by Adly et al (19) is shown in Table 2. 
It is noteworthy that the recurring splice-site variant is 
associated with postaxial polydactyly, but variable ocular 
(reduced visual acquity or microphthalmia with colo-
boma) and oral (highly arched/ cleft palate with or without 
midline tongue groove) phenotypes (Table 2), consistent 
with variable expressivity. In contrast, the Finnish siblings 
carrying 2 other loss-of-function variants in TBC1D32 did 
not exhibit postaxial polydactyly but had variable intel-
lectual and ocular phenotypes. A unifying theme in all 4 
patients reported to date, however, is the pituitary gland 
phenotype, with variable pituitary hormone deficiencies 
(Table 2). The CNS phenotype of the aborted fetus is not 
available; however, the fetus also carried the homozygous 
TBC1D32 p.Arg411_Gly458del truncation and displayed 
cleft lip and intestinal malrotation, adding the latter feature 
to the list of associated phenotypes in biallelic TBC1D32 
Figure 2. Human expression of TBC1D32 mRNA transcripts in transverse brain sections at different developmental stages during embryogenesis. 
A: There is no clear expression in the hypothalamus, Rathke’s pouch, or elsewhere in the brain when comparing results using the antisense probe 
and the sense probe at Carnegie stage (CS) 19. B: At CS20 there may be some partial expression in the hypothalamus using the antisense probe; 
however, staining is very similar to the Rathke’s pouch and the hypothalamus when using the control sense probe, where some background 
staining is noted. C: At CS23, there is partial expression in the trigeminal ganglia, in Rathke’s pouch, and along the hypothalamus when comparing 
the antisense and control sense probes. D: There is strong expression in the hindbrain, in particular the thalamus, with some expression also seen in 
the choroid plexus. Abbreviations: CP, choroid plexus; Hyp, hypothalamus; RP, Rathke’s pouch; T, thalamus; Tri, trigeminal ganglia.
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loss-of-function variant carriers. Human gene expression 
analysis in our study identified TBC1D32 expression in 
the developing hypothalamus and pituitary gland (CS23) 
(Fig.  2C) and in the pituitary and hypothalamic cDNA 
libraries of adults (Fig.  3), suggesting activation of this 
gene during the early stages of hypothalamo-pituitary for-
mation during embryogenesis, which is maintained into 
adulthood. Furthermore, the strong TBC1D32 expression 
seen in other areas of the hindbrain (Fig. 2D) suggests that 
TBC1D32 plays a role in other regions of the brain during 
development, possibly reflective of the complex variable 
CNS problems seen in OFDS patients such as ours.
Previous proteomic analysis of cilia has confirmed 
that TBC1D32 is a ciliary protein (26). Cilia can be 
motile or nonmotile (primary cilia) and are specialized 
microtubule-based sensory organelles (27), which play 
a role in cell polarity determination and in mediating 
vital signaling cascades such as the SHH signaling 
pathway (28). Therefore, the correct development of 
cilia is a prerequisite for SHH signaling. Deletion of 
the Tbc1d32 homolog in mice, referred to as the Bromi 
mouse, causes a severe phenotype encompassing devel-
opmental defects, including a lack of the neural tube 
floor plate, exencephaly, signs of defective ventral neural 
fate specification, poorly developed eyes, and preaxial 
Figure 3. Reverse transcriptase PCR analysis of TBC1D32 expression. 
A 310-bp fragment of transcript encoding TBC1D32 was amplified 
from human pituitary gland cDNA and from hypothalamic 
cDNA (QUICK-Clone pituitary cDNA, Takarabio, 1.5µl / reaction; 
Hypothalamus Marathon®-Ready cDNA, Takarabio, 1.5ul / reaction). 
Human GAPDH was used as a reference gene. The PCR products were 
visualized on a 1.0% agarose gel. Abbreviations: c, negative control 
without DNA template; ht, hypothalamus; p, pituitary gland.
Figure 4. The functional grouping of the high confidence interacting proteins of TBC1D32. Interactome analysis reveals known and novel 
interactions for TBC1D32. AP-MS and BioID analysis of TBC1D32 identified 81 high-confidence protein–protein interactions (yellow lines represent 
interaction detected by AP-MS approach; green lines represent interactions detected by BioID approach; overlap of the 2 purification methods is 
shown with grey lines; known interaction is shown with a dashed line). The interacting proteins are grouped based on their molecular functions/
complexes.
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polydactyly. Electron microscopy of the neuroepithe-
lium in these mice showed curled axonemes surrounded 
by dilated ciliary membranes. These studies showed 
that Bromi-mutant neurons were associated with de-
ficient Shh signaling activation of downstream regu-
lators Gli2 and Gli3, and that Tbc1d32 is critical for 
the correct localization of Gli2 within the cilium (10). 
A similar phenotype to the Bromi mouse was also noted 
in morpholino-mediated knockdown studies of the gene 
homolog in zebrafish (10). Hence, these studies provide 
a clear link between ciliary morphology and the cor-
rect localization of Gli2 in the cilia, and suggest that 
the hypopituitary phenotype observed in association 
with TBC1D32 variants in humans is likely the result 
of GLI2 mislocalization. Recently, mutation in IFT172 
has been associated with a phenotype characterized by 
anterior pituitary hypoplasia, an ectopic posterior pi-
tuitary, retinopathy, metaphyseal dysplasia, and renal 
failure (29). IFT172 has been implicated in ciliary func-
tion, and hence our study provides further support for 
the role of cilia in hypothalamo-pituitary disease.
In mammalian cells, primary cilia are essential for 
SHH signaling (30), and in protein–protein interaction 
studies we identified 10 proteins of HCIPs that are in-
volved in the assembly of primary cilia (Fig.  4). Our 
analyses confirmed that TBC1D32 interacts with his-
tone deacetylase 1 (HDAC1), a protein implicated in 
SHH signaling (31), and interacts with 2 additional prey 
proteins (FKBP8, DHCR7) that regulate SHH signaling 
(32–37) (Fig.  4). Furthermore, the loss of mouse cell 
cycle-related kinase (CCRK) function, a protein known 
to interact with TBC1D32 (10), has been shown to re-
sult in a highly similar embryonic phenotype to that 
of the Bromi-null mouse, resulting in disrupted optic 
cup and lens formation, shortened optic stalk, reduced 
neural retina specification, and ectopic retinal pigment 
epithelium formation (10, 38, 39). Although our experi-
ment using a human cell line did not find an association 
with CCRK, 5 TBC1D32-interacting proteins (CI114, 
UHRF1, AURKB, CENPV, SVIL) were associated with 
positive regulation of cytokinesis and the cell cycle 
(Fig. 4). Taken together, proteomics provided a conceiv-
able link between TBC1D32 and the developmental de-
fects of the pituitary gland and the eye. Although we 
found a connection between TBC1D32 and regulators 
of the immune system, its association with the recur-
rent ear infections seen in all the patients and the unex-
pected death of patient I.3 remains to be established. It 
is important to note, however, that patients I.5 and II.8 
do not have a history of recurrent or severe infections. 
Immune function or ciliary function have not been 
examined in detail in any of the patients.
To conclude, we describe 3 patients and an aborted 
fetus with biallelic variants in TBC1D32¸ a ciliary gene 
implicated in SHH signaling and leading to the correct 
localization of Gli2, a protein that is significantly im-
plicated in the aetiology of congenital hypopituitarism 
and related disorders. The available evidence to date 
suggests that this defect should be suspected in patients 
with pituitary hormone deficiencies and craniofacial 
phenotypes, even in the absence of retinal dystrophy, 
oral phenotype, intellectual disability, or postaxial poly-
dactyly. Finally, our results generated a developmental 
human brain expression profile of TBC1D32, con-
firmed the role of TBC1D32 as an interacting partner 
of HDAC1, and highlighted its connections to cilia as-
sembly, SHH signal transduction, the immune system, 
and the regulation of the cell cycle. The immune system 
and cell cycle–related TBC1D32 functions may modify 
the phenotype of patients with TBC1D32 mutations, 
and suggest an interesting direction for future studies.
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